Nonalcoholic Steatohepatitis - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Nonalcoholic Steatohepatitis - Pipeline Insight, 2021,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nonalcoholic Steatohepatitis: Overview
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells. In NASH, there is an abnormal amount of fat in the liver cells, but, in addition, in NASH, there is inflammation within the liver, and, as a result, the liver cells are damaged, they die, and are replaced by scar tissue. NASH usually does not cause symptoms. Most people who have NASH feel fine and do not know that they have it. As NASH progresses and liver damage gets worse, a patient may start to have symptoms such as Fatigue, Weight loss, General weakness, and acne in the upper right part of the belly.
'Nonalcoholic Steatohepatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonalcoholic Steatohepatitis pipeline landscape is provided which includes the disease overview and Nonalcoholic Steatohepatitis treatment guidelines. The assessment part of the report embraces, in depth Nonalcoholic Steatohepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonalcoholic Steatohepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Nonalcoholic Steatohepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nonalcoholic Steatohepatitis Emerging Drugs
Further product details are provided in the repor
Nonalcoholic Steatohepatitis: Therapeutic Assessment
This segment of the report provides insights about the different Nonalcoholic Steatohepatitis drugs segregated based on following parameters that define the scope of the report, such as:
Nonalcoholic Steatohepatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nonalcoholic Steatohepatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonalcoholic Steatohepatitis drugs.
Nonalcoholic Steatohepatitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Nonalcoholic Steatohepatitis - Pipeline Insight, 2021,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nonalcoholic Steatohepatitis: Overview
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells. In NASH, there is an abnormal amount of fat in the liver cells, but, in addition, in NASH, there is inflammation within the liver, and, as a result, the liver cells are damaged, they die, and are replaced by scar tissue. NASH usually does not cause symptoms. Most people who have NASH feel fine and do not know that they have it. As NASH progresses and liver damage gets worse, a patient may start to have symptoms such as Fatigue, Weight loss, General weakness, and acne in the upper right part of the belly.
'Nonalcoholic Steatohepatitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonalcoholic Steatohepatitis pipeline landscape is provided which includes the disease overview and Nonalcoholic Steatohepatitis treatment guidelines. The assessment part of the report embraces, in depth Nonalcoholic Steatohepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonalcoholic Steatohepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nonalcoholic Steatohepatitis R&D. The therapies under development are focused on novel approaches to treat/improve Nonalcoholic Steatohepatitis.
This segment of the Nonalcoholic Steatohepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nonalcoholic Steatohepatitis Emerging Drugs
- Semaglutide: Novo Nordisk
- Resmetirom: Madrigal Pharmaceuticals
- Oltipraz: PharmaKing
- ALS-L1023: AngioLab
- ORMD-0801: Oramed
- CB4211: CohBar
Further product details are provided in the repor
Nonalcoholic Steatohepatitis: Therapeutic Assessment
This segment of the report provides insights about the different Nonalcoholic Steatohepatitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nonalcoholic Steatohepatitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Hepatoprotectant
- Small molecule
- Cell therapy
- Antisense oligonucleotides
- Recombinant proteins
- Small interfering RNA
- Product Type
Nonalcoholic Steatohepatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nonalcoholic Steatohepatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonalcoholic Steatohepatitis drugs.
Nonalcoholic Steatohepatitis Report Insights
- Nonalcoholic Steatohepatitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nonalcoholic Steatohepatitis drugs?
- How many Nonalcoholic Steatohepatitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nonalcoholic Steatohepatitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nonalcoholic Steatohepatitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nonalcoholic Steatohepatitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novo Nordisk
- Madrigal Pharmaceuticals
- PharmaKing
- Cirius Therapeutics
- Inventiva Pharma
- Galmed Pharmaceuticals
- AbbVie
- Galectin Therapeutics
- Viking Therapeutics
- Sagimet Biosciences
- Novartis
- Hepion Pharmaceuticals
- Celgene
- Boston Pharmaceuticals
- Bristol-Myers Squibb
- NGM Biopharmaceuticals
- Boehringer Ingelheim
- Axcella Health
- Corcept Therapeutics
- TaiwanJ Pharmaceuticals
- AngioLab
- Oramed
- Can-Fite Biopharma
- Mitsubishi Tanabe Pharma
- MediciNova
- Merck Sharp & Dohme
- Metacrine
- MedImmune
- Lipocine
- Chemomab Therapeutics
- Afimmune
- NorthSea Therapeutics
- Rivus Pharmaceuticals
- HighTide Biopharma
- Hanmi Pharmaceutical
- ENYO Pharma
- Histogen
- Akero Therapeutics
- Enanta Pharmaceuticals
- Gilead Sciences
- Ionis Pharmaceuticals
- Eli Lilly and Company
- Terns Pharmaceuticals
- Sinew Pharma
- Poxel
- CytoDyn
- Future Medicine
- 89bio Ltd.
- HK inno.N
- Arrowhead Pharmaceuticals
- Promethera Biosciences
- Enanta Pharmaceuticals
- Semaglutide
- Resmetirom
- Oltipraz
- MSDC-0602K
- Lanifibranor
- Aramchol
- Cenicriviroc
- Belapectin
- VK2809
- TVB-2640
- Tropifexor (LJN452)
- CRV431
- CC-90001
- BOS-580
- BMS-986263
- Aldafermin
- BI 456906
- AXA1125
- Miricorilant
- JKB-122
- ALS-L1023
- ORMD-0801
- Namodenoson
- MN-001
- MT-3995
- MK-3655
- MET642
- MEDI 0382
- LYS006
- LPCN 1144
- CM101
- Epeleuton
- Icosabutate
- HU6
- HTD1801
- HM15211
- EPY001a
- Emricasan
- Efruxifermin (EFX)
- EDP-305
- Firsocostat
- ION224
- Tirzepatide
- TERN-101
- SNP-610
- PXL770
- Leronlimab
- FM101
- BIO89-100
- IN-A010
- ARO-HSD
- HepaStem
- EDP-297
Introduction
Executive Summary
Nonalcoholic Steatohepatitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nonalcoholic Steatohepatitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nonalcoholic Steatohepatitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nonalcoholic Steatohepatitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Resmetirom: Madrigal Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALS-L1023: AngioLab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CB4211: CohBar
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
ALG-055009: Aligos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nonalcoholic Steatohepatitis Key Companies
Nonalcoholic Steatohepatitis Key Products
Nonalcoholic Steatohepatitis- Unmet Needs
Nonalcoholic Steatohepatitis- Market Drivers and Barriers
Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
Nonalcoholic Steatohepatitis Analyst Views
Nonalcoholic Steatohepatitis Key Companies
Appendix
Executive Summary
Nonalcoholic Steatohepatitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nonalcoholic Steatohepatitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nonalcoholic Steatohepatitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nonalcoholic Steatohepatitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Resmetirom: Madrigal Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALS-L1023: AngioLab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CB4211: CohBar
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
ALG-055009: Aligos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nonalcoholic Steatohepatitis Key Companies
Nonalcoholic Steatohepatitis Key Products
Nonalcoholic Steatohepatitis- Unmet Needs
Nonalcoholic Steatohepatitis- Market Drivers and Barriers
Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
Nonalcoholic Steatohepatitis Analyst Views
Nonalcoholic Steatohepatitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Nonalcoholic Steatohepatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Nonalcoholic Steatohepatitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Nonalcoholic Steatohepatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Nonalcoholic Steatohepatitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
